Concepts (113)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Tuberculoma, Intracranial | 1 | 2018 | 7 | 0.77 | Why? |
| Tuberculosis, Miliary | 1 | 2018 | 66 | 0.68 | Why? |
| Endocarditis | 1 | 2016 | 368 | 0.44 | Why? |
| Neuroimaging | 1 | 2018 | 1106 | 0.43 | Why? |
| Paris | 4 | 2021 | 1287 | 0.34 | Why? |
| Staphylococcal Infections | 1 | 2016 | 1099 | 0.33 | Why? |
| Middle East Respiratory Syndrome Coronavirus | 2 | 2019 | 8843 | 0.33 | Why? |
| Delayed Diagnosis | 1 | 2016 | 1529 | 0.32 | Why? |
| Magnetic Resonance Imaging | 1 | 2018 | 6551 | 0.22 | Why? |
| Anti-N-Methyl-D-Aspartate Receptor Encephalitis | 1 | 2020 | 82 | 0.20 | Why? |
| Capsules | 1 | 2018 | 140 | 0.18 | Why? |
| Saudi Arabia | 2 | 2019 | 4423 | 0.18 | Why? |
| Hydroxyurea | 1 | 2017 | 87 | 0.16 | Why? |
| Spermatogenesis | 1 | 2017 | 126 | 0.16 | Why? |
| Infectious Disease Medicine | 1 | 2019 | 311 | 0.16 | Why? |
| Yellow fever virus | 1 | 2018 | 205 | 0.16 | Why? |
| Chlorhexidine | 1 | 2018 | 176 | 0.15 | Why? |
| Anti-Bacterial Agents | 4 | 2019 | 10083 | 0.15 | Why? |
| Yellow Fever | 1 | 2018 | 231 | 0.14 | Why? |
| Hospitalization | 5 | 2021 | 54280 | 0.14 | Why? |
| Oseltamivir | 1 | 2018 | 583 | 0.13 | Why? |
| Fecal Microbiota Transplantation | 1 | 2018 | 372 | 0.13 | Why? |
| Hydroxychloroquine | 3 | 2021 | 12447 | 0.13 | Why? |
| Streptococcus pneumoniae | 1 | 2018 | 827 | 0.12 | Why? |
| Ageusia | 1 | 2020 | 918 | 0.12 | Why? |
| Hygiene | 1 | 2019 | 987 | 0.12 | Why? |
| Travel | 3 | 2019 | 7220 | 0.11 | Why? |
| Exanthema | 1 | 2021 | 1097 | 0.11 | Why? |
| Tomography, X-Ray Computed | 1 | 2018 | 25144 | 0.11 | Why? |
| Clostridium Infections | 1 | 2018 | 595 | 0.11 | Why? |
| Camelus | 1 | 2019 | 1425 | 0.11 | Why? |
| Anemia, Sickle Cell | 1 | 2017 | 546 | 0.11 | Why? |
| Travel-Related Illness | 1 | 2018 | 1357 | 0.10 | Why? |
| Disease Reservoirs | 1 | 2019 | 1672 | 0.10 | Why? |
| Chilblains | 1 | 2021 | 1156 | 0.10 | Why? |
| Escherichia coli | 1 | 2018 | 1547 | 0.10 | Why? |
| Neurology | 1 | 2020 | 1613 | 0.09 | Why? |
| Drug Resistance, Bacterial | 1 | 2018 | 1414 | 0.09 | Why? |
| Compassionate Use Trials | 2 | 2021 | 632 | 0.08 | Why? |
| Symptom Assessment | 1 | 2019 | 4967 | 0.07 | Why? |
| Coronavirus Infections | 3 | 2019 | 253789 | 0.07 | Why? |
| Occupational Diseases | 1 | 2020 | 2787 | 0.07 | Why? |
| Communicable Diseases, Emerging | 1 | 2019 | 2523 | 0.07 | Why? |
| Survival Rate | 1 | 2019 | 9206 | 0.07 | Why? |
| Renal Insufficiency, Chronic | 1 | 2019 | 2654 | 0.07 | Why? |
| Patient Isolation | 1 | 2018 | 3182 | 0.07 | Why? |
| Oxygen Inhalation Therapy | 1 | 2018 | 3629 | 0.07 | Why? |
| Chiroptera | 1 | 2019 | 3530 | 0.07 | Why? |
| Retrospective Studies | 5 | 2021 | 105322 | 0.06 | Why? |
| Disease Management | 1 | 2019 | 6841 | 0.06 | Why? |
| Extracorporeal Membrane Oxygenation | 1 | 2019 | 5002 | 0.05 | Why? |
| Biotransformation | 1 | 2019 | 74 | 0.05 | Why? |
| Humans | 18 | 2021 | 930598 | 0.05 | Why? |
| Middle Aged | 9 | 2021 | 270681 | 0.05 | Why? |
| Aged | 7 | 2021 | 215776 | 0.05 | Why? |
| Epidemics | 1 | 2019 | 6407 | 0.05 | Why? |
| Antisickling Agents | 1 | 2017 | 28 | 0.05 | Why? |
| France | 3 | 2020 | 12074 | 0.05 | Why? |
| Male | 10 | 2021 | 367725 | 0.04 | Why? |
| Viral Vaccines | 1 | 2019 | 7560 | 0.04 | Why? |
| Outpatients | 2 | 2021 | 3417 | 0.04 | Why? |
| Sperm Count | 1 | 2017 | 72 | 0.04 | Why? |
| Treatment Outcome | 3 | 2021 | 51732 | 0.04 | Why? |
| Pneumonia | 1 | 2018 | 5652 | 0.04 | Why? |
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 9706 | 0.04 | Why? |
| Genome, Viral | 1 | 2019 | 13157 | 0.04 | Why? |
| Adult | 9 | 2021 | 244371 | 0.04 | Why? |
| Female | 9 | 2021 | 380317 | 0.04 | Why? |
| Prescription Drugs | 1 | 2019 | 243 | 0.04 | Why? |
| Global Health | 1 | 2019 | 13911 | 0.04 | Why? |
| Antiviral Agents | 2 | 2019 | 41703 | 0.04 | Why? |
| Outpatient Clinics, Hospital | 1 | 2020 | 523 | 0.04 | Why? |
| General Practitioners | 1 | 2020 | 568 | 0.03 | Why? |
| Secondary Prevention | 1 | 2018 | 762 | 0.03 | Why? |
| Vomiting | 1 | 2018 | 722 | 0.03 | Why? |
| Myalgia | 1 | 2018 | 1015 | 0.03 | Why? |
| Drug Monitoring | 1 | 2019 | 1408 | 0.03 | Why? |
| Young Adult | 2 | 2018 | 93724 | 0.03 | Why? |
| Risk Factors | 1 | 2019 | 71621 | 0.03 | Why? |
| Animals | 1 | 2019 | 78931 | 0.03 | Why? |
| Dose-Response Relationship, Drug | 1 | 2019 | 3776 | 0.02 | Why? |
| Health Surveys | 1 | 2021 | 2841 | 0.02 | Why? |
| Telemedicine | 1 | 2021 | 25032 | 0.02 | Why? |
| Hospitals, University | 1 | 2021 | 4173 | 0.02 | Why? |
| Microbial Sensitivity Tests | 1 | 2018 | 2886 | 0.02 | Why? |
| Epidemiological Monitoring | 1 | 2021 | 3493 | 0.02 | Why? |
| Laboratories | 1 | 2020 | 2858 | 0.02 | Why? |
| Prognosis | 2 | 2021 | 32490 | 0.02 | Why? |
| Cohort Studies | 2 | 2021 | 36005 | 0.02 | Why? |
| Immunotherapy | 1 | 2020 | 2421 | 0.02 | Why? |
| Evidence-Based Medicine | 1 | 2019 | 3228 | 0.02 | Why? |
| Time Factors | 2 | 2021 | 31397 | 0.02 | Why? |
| Kidney | 1 | 2019 | 3648 | 0.02 | Why? |
| Sex Factors | 1 | 2021 | 11014 | 0.02 | Why? |
| Ambulatory Care | 1 | 2020 | 4947 | 0.02 | Why? |
| Immunocompromised Host | 1 | 2019 | 5150 | 0.01 | Why? |
| Primary Health Care | 1 | 2020 | 4839 | 0.01 | Why? |
| Hospitals | 1 | 2021 | 11793 | 0.01 | Why? |
| Brazil | 1 | 2018 | 12582 | 0.01 | Why? |
| Immunoglobulin M | 1 | 2018 | 9091 | 0.01 | Why? |
| Obesity | 1 | 2021 | 7388 | 0.01 | Why? |
| Age Factors | 1 | 2021 | 21039 | 0.01 | Why? |
| Follow-Up Studies | 1 | 2018 | 17020 | 0.01 | Why? |
| Aged, 80 and over | 2 | 2021 | 88759 | 0.01 | Why? |
| Real-Time Polymerase Chain Reaction | 1 | 2018 | 11367 | 0.01 | Why? |
| Prevalence | 1 | 2020 | 25773 | 0.01 | Why? |
| Comorbidity | 1 | 2021 | 34796 | 0.01 | Why? |
| Prospective Studies | 1 | 2021 | 43301 | 0.01 | Why? |
| Practice Guidelines as Topic | 1 | 2019 | 15421 | 0.01 | Why? |
| Immunoglobulin G | 1 | 2018 | 21571 | 0.01 | Why? |
| Pandemics | 1 | 2021 | 389249 | 0.01 | Why? |
| Cross-Sectional Studies | 1 | 2020 | 53120 | 0.01 | Why? |
| Intensive Care Units | 1 | 2018 | 29594 | 0.01 | Why? |
Bleibtreu's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(113)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(115)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_